Healthcare sector offers diversification against tech concentration

Investment analysts are highlighting the healthcare sector as a strategic tool for portfolio diversification and a hedge against high concentration in technology stocks. Schroders notes that healthcare is currently trading at one of its steepest relative discounts to the broader market in over two decades, as investor capital has shifted toward AI and defense sectors.

Growth in healthcare is expected to be driven by structural, non-cyclical factors such as a rapidly aging global population. Furthermore, the sector shows a low 52-week return correlation with technology stocks, potentially offering stability if momentum in mega-cap tech falters.

On a company level, specific interest is noted in Australian healthcare firms. CSL Ltd is undergoing a business reset with significant investments in US plasma manufacturing to meet growing demand for immunoglobulin. Cochlear Ltd is also identified as a long-term opportunity, focused on expanding access to cochlear implants, particularly within the adult market.